Sonnet BioTherapeutics Holdings, Inc. SONN
Set alert
At close · Dec 2
- YTD
- -13.70%
- 1 year
- -51.72%
- Open
- 3.16
- Prev close
- 1.26
- Mkt cap
- 4.33M
- Vol
- 10.43M
- Avg vol
- 1.33M
- EPS
- -11.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.26
- High
- 3.23
- Forward P/E
- -0.10
- Beta
- 1.04
- Short ratio
- 0.03
- Inst. own
- 0.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 3.46
- 200-d avg
- 8.63
- 1y target
- 160.00
Key statistics
- Market cap
- 4.33M
- Enterprise value
- -2.23M
- Trailing P/E
- 0.00
- Forward P/E
- -0.10
- PEG ratio
- 0.00
- Price / sales
- 77.50
- Price / book
- 0.36
- EPS (TTM)
- -11.35
- Beta
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 55.88K
- Revenue growth
- 0.00%
- Free cash flow
- -9.88M
- Total cash
- 3.55M
- Total debt
- 150.19K
- Return on equity
- -264.57%
- Shares outstanding
- 3.01M
- Short % of float
- 4.85%
- 50-day average
- 3.46
- 200-day average
- 8.63
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -11.12.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Dec 19, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -5.60 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | 0.56 | — | — |
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | -2.48 | — | — |
| Dec 18, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 23, 2024 | Chardan Capital | main | Buy | Buy |
| May 28, 2024 | Chardan Capital | main | Buy | Buy |
| May 16, 2024 | EF Hutton | main | Buy | Buy |
| Feb 15, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 27, 2023 | Ladenburg Thalmann | init | — | Buy |
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sonnetbio.com
News
- Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
- 12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on SONN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHATT NAILESH | Director | Stock Award(Grant) | Dec 10, 2023 | 547 |
| CINI JOHN K | Officer | Stock Award(Grant) | Dec 10, 2023 | 2,116 |
| CROSS JOHN HARRY | Chief Financial Officer | Stock Award(Grant) | Dec 10, 2023 | 1,588 |
| DEXTER SUSAN | Chief Technology Officer | Stock Award(Grant) | Dec 10, 2023 | 1,643 |
| DYRNESS ALBERT D | Director | Stock Award(Grant) | Dec 10, 2023 | 537 |
| GRIFFITH DONALD J. CPA | Director | Stock Award(Grant) | Dec 10, 2023 | 375 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.01% | 378 | 544 | Sep 29, 2024 |
| Blackrock Inc. | 0.00% | 65 | 93 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.10% | 3,004 | 4.33K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.06% | 1,841 | 2.65K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 1,418 | 2.04K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 850 | 1.22K | Oct 30, 2024 |